Motley Fool Backs 3 Growth Stocks for $5,000 as Credo Revenue Tops $1.34 Billion
Updated
Updated · The Motley Fool · Jun 5
Motley Fool Backs 3 Growth Stocks for $5,000 as Credo Revenue Tops $1.34 Billion
3 articles · Updated · The Motley Fool · Jun 5
Summary
Three lesser-followed companies — Credo, Cellebrite and TransMedics — were highlighted as $5,000 growth-stock picks for investors willing to buy through market volatility.
Credo led the case with fiscal 2026 revenue of $1.34 billion, more than triple a year earlier, plus a $750 million DustPhotonics deal that expands it from copper links into optical AI data-center connectivity.
Cellebrite was pitched on recurring software revenue, with annual recurring revenue up 21%, subscription sales at $96.5 million in the first quarter, and a potential five-year, $100 million U.S. government renewal supporting its AI-enabled forensics tools.
TransMedics rounded out the list with first-quarter revenue up 21% to $173.9 million and full-year guidance of $727 million to $757 million, driven by its organ-preservation system and in-house logistics network.
The broader argument was that all three operate in specialized markets with high switching costs or limited competition, giving them room to compound growth over the long term.